Literature DB >> 25550850

Clinical significance of TMPRSS4 in prostate cancer.

Guohai Shi1, Xiaoqun Yang2, Bo Dai1, Hailiang Zhang1, Yijun Shen1, Yao Zhu1, Yiping Zhu1, Wenjun Xiao1, Chunguang Ma1, Linguo Wen1, Xiaojian Qin1, Dalong Cao1, Dingwei Ye1.   

Abstract

Transmembrane protease serine 4 (TMPRSS4) is a type-II transmembrane serine protease that plays an important role in the migration of cancer cells. This study aimed to investigate both the expression of TMPRSS4 and its clinical significance in prostate cancer. The expression of TMPRSS4 was evaluated in 73 pairs of prostate cancer and adjacent non-cancerous tissues by immunohistochemistry. The level of TMPRSS4 in prostate cancer tissues was significantly higher than that in adjacent non-cancerous tissues. High TMPRSS4 expression was significantly associated with advanced TNM stage and LNM. No association between TMPRSS4 expression and progression-free survival was observed in all patients. Stratified analyses according to clinical features revealed that patients with low TMPRSS4 expression had poor prognosis compared with those with high TMPRSS4 expression in subjects not receiving neoadjuvant chemotherapy. In conclusion, TMPRSS4 showed abnormal expression in prostate cancer tissues. TMPRSS4 may be a potential prognostic biomarker for prostate cancer patients who did not undergo neoadjuvant chemotherapy.

Entities:  

Keywords:  Transmembrane protease; biomarker; neoadjuvant chemotherapy; prognosis; prostatic cancer; serine 4

Mesh:

Substances:

Year:  2014        PMID: 25550850      PMCID: PMC4270561     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes.

Authors:  J D Hooper; J A Clements; J P Quigley; T M Antalis
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Authors:  Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta
Journal:  BMC Med Genomics       Date:  2008-04-28       Impact factor: 3.063

3.  Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Xuelin Zhang; Chengzhi He; Chunya He; Baofu Chen; Yanxia Liu; Min Kong; Chunguo Wang; Lizhong Lin; Yan Dong; Haihui Sheng
Journal:  Pathol Res Pract       Date:  2013-06-28       Impact factor: 3.250

4.  Prognostic value of TMPRSS4 expression in patients with breast cancer.

Authors:  Bin Liang; Mingzhe Wu; Yuehua Bu; Ainong Zhao; Fang Xie
Journal:  Med Oncol       Date:  2013-02-19       Impact factor: 3.064

Review 5.  Screening for prostate cancer.

Authors:  Dragan Ilic; Molly M Neuberger; Mia Djulbegovic; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 6.  Type II transmembrane serine proteases in development and disease.

Authors:  Roman Szabo; Thomas H Bugge
Journal:  Int J Biochem Cell Biol       Date:  2007-12-04       Impact factor: 5.085

7.  Clinical implication of TMPRSS4 expression in human gallbladder cancer.

Authors:  Xiao-Yang Wu; Li Zhang; Ke-Ming Zhang; Ming-Hua Zhang; Ting-Yan Ruan; Chao-Ying Liu; Jun-Ying Xu
Journal:  Tumour Biol       Date:  2014-02-15

8.  Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.

Authors:  Tri-Hung Nguyen; William Weber; Evis Havari; Timothy Connors; Rebecca G Bagley; Rajashree McLaren; Prashant R Nambiar; Stephen L Madden; Beverly A Teicher; Bruce Roberts; Johanne Kaplan; Srinivas Shankara
Journal:  Int J Oncol       Date:  2012-06-12       Impact factor: 5.650

9.  TMPRSS4 as a poor prognostic factor for triple-negative breast cancer.

Authors:  Daye Cheng; Hong Kong; Yunhui Li
Journal:  Int J Mol Sci       Date:  2013-07-12       Impact factor: 5.923

10.  Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters.

Authors:  Zhong Lu; Li Qi; Xue Jun Bo; Guo Dong Liu; Jun Ming Wang; Guixin Li
Journal:  J Res Med Sci       Date:  2013-08       Impact factor: 1.852

View more
  3 in total

1.  TMPRSS4 Upregulates TWIST1 Expression through STAT3 Activation to Induce Prostate Cancer Cell Migration.

Authors:  Zhang Jianwei; Li Qi; Xu Quanquan; Wang Tianen; Wang Qingwei
Journal:  Pathol Oncol Res       Date:  2017-05-02       Impact factor: 3.201

Review 2.  TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis.

Authors:  Ping Zeng; Peng Zhang; Li-Na Zhou; Min Tang; Yi-Xin Shen; Jun Jin; Ya-Qun Zhu; Min-Bin Chen
Journal:  Oncotarget       Date:  2016-11-15

3.  SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells.

Authors:  Jungsug Gwak; Jee Yoon Shin; Kwanghyun Lee; Soon Ki Hong; Sangtaek Oh; Sung-Ho Goh; Won Sun Kim; Bong Gun Ju
Journal:  Oncotarget       Date:  2016-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.